SER Serina Therapeutics, Inc.

CIK 0001708599 50 ready 8-Ks latest June 24, 2026, 4:10 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 24, 2026, 4:10 PM ET

Top materiality 1.00

Event mix other_material ×19 · earnings ×10 · leadership ×9

Sentiment 13 pos · 9 neg · 28 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for SER

Highest-materiality recent filing

AgeX completes reverse merger with Serina; becomes Serina Therapeutics, trades as SER

April 1, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 1.01 item 9.01 item 2.03 item 3.03 item 5.01 item 5.02 item 5.03 item 8.01 ◈ executive_change ×5◈ Debt Financings◈ Governance Changes◈ M&A Transactions◈ Material Agreements

Merger closed March 26, 2024; Serina shares converted at 0.97682654 per AgeX share; 5,913,277 shares issued to Serina stockholders.
Post-merger ~10.1M shares outstanding (fully diluted excl. warrants); Serina equityholders own ~75%, AgeX legacy ~25%.

Read filing →

June 24, 2026, 4:10 PM ET other material materiality 0.70 neutral item 5.03 item 5.07 item 9.01

Serina increases authorized common stock from 40M to 125M; equity plan expanded by 2M shares

Authorized common stock increased from 40,000,000 to 125,000,000 shares via filed certificate of amendment.
May 14, 2026, 4:05 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway

Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
March 25, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed

Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.
March 23, 2026, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 5.02 item 5.03 item 7.01 item 9.01 ◈ Material Agreements ×2◈ Governance Changes

Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman

First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
January 28, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's

FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.
January 15, 2026, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 7.01 item 9.01 ◈ Listing & Compliance Notices

Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M

Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.
December 10, 2025, 6:59 PM ET regulatory materiality 0.70 neutral item 8.01 item 9.01

Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program

Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.
November 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold

Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.
November 3, 2025, 6:59 PM ET regulatory materiality 0.85 negative item 8.01 item 9.01

Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease

FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.
October 6, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial

Received $5 million initial tranche under up to $20 million convertible note financing agreement.
September 15, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Equity Issuances ×2◈ Debt Financings

Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b

Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.
September 9, 2025, 7:59 PM ET debt materiality 0.65 positive item 7.01 item 9.01

Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial

Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.
August 25, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway

FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.
August 11, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year

Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).
May 22, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change ×2

Serina appoints ex-Karuna CMO Brannan to board; director Gross departs

Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.
May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Serina Therapeutics Q1 net loss $4.8M; cash runway through Q3 2025

Net loss attributable to Serina of $4.8M ($0.49/share) vs $15.0M ($5.38/share) in Q1 2024.
April 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Serina Therapeutics enters ATM facility for up to $13.3M common stock sale

Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of up to $13,270,500 in common stock.
April 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252

Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.
March 24, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting

Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.
March 24, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023

Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.
February 3, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Serina Therapeutics closes $5M second tranche of equity financing at 113% premium

Received second $5M tranche of $10M equity financing from JuvVentures (UK) Limited.
December 26, 2024, 6:59 PM ET M&A materiality 0.75 neutral item 1.01 item 2.01 item 9.01 ◈ M&A Transactions

Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt

Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.
December 11, 2024, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Serina Therapeutics presents data showing POZ-lipid avoids anti-PEG immune response in animal model

POZ-lipid did not induce IgM or IgG antibody responses after repeated administration in an animal model.
December 2, 2024, 6:59 PM ET other material materiality 0.70 positive item 1.01 item 3.02 item 8.01 item 9.01

Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)

Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.
November 12, 2024, 6:59 PM ET earnings materiality 0.90 negative item 2.02 item 9.01

Serina Therapeutics reports Q3 net income of $1.4M but raises going concern doubt as cash stands at $3.2M

Net income $1.4M ($0.16 basic EPS) vs $1.8M a year ago; revenue $14k from NIH grants.
September 12, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change

Serina Therapeutics appoints Steven Ledger as permanent CEO; base $450k, options grant

Steven Ledger, interim CEO since March 2024, appointed permanent CEO effective Sept 8, 2024.
August 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Serina Therapeutics appoints Gregory S. Curhan as CFO, replaces departing interim CFO Andrea Park

Gregory S. Curhan appointed CFO effective Aug 16, 2024; compensated at $650/hour plus 250k-share option vesting over 48 months.
August 9, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt

Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.
May 14, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

Serina Therapeutics Q1 net loss $9.4M; going concern substantial doubt

Net loss of $9.4M ($3.38/share) vs net income of $1.7M in Q1 2023.
April 1, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 1.01 item 9.01 item 2.03 item 3.03 item 5.01 item 5.02 item 5.03 item 8.01 ◈ executive_change ×5◈ Debt Financings◈ Governance Changes◈ M&A Transactions◈ Material Agreements

AgeX completes reverse merger with Serina; becomes Serina Therapeutics, trades as SER

Merger closed March 26, 2024; Serina shares converted at 0.97682654 per AgeX share; 5,913,277 shares issued to Serina stockholders.
March 22, 2024, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 9.01 ◈ Earnings Releases

AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt

Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).